methyl 2,3,4-(tri-O-acetyl-α-D-glucopyranosyl bromide)uronate | 6205-83-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2,3,4-(tri-O-acetyl-α-D-glucopyranosyl bromide)uronate
• 英文别名: 2,3,4-tri-O-acetyl-1-bromo-α-D-glucopyranuronic acid；(2S)-3t,4c,5t-triacetoxy-6t-bromo-tetrahydro-pyran-2r-carboxylic acid；(2S)-3t,4c,5t-Triacetoxy-6t-brom-tetrahydro-pyran-2r-carbonsaeure；1-Brom-tri-O-acetyl-1-desoxy-α-D-gluco-pyranuronsaeure；(2S,3S,4S,5R,6R)-3,4,5-triacetyloxy-6-bromooxane-2-carboxylic acid
• CAS: 6205-83-0
• 化学式: C₁₂H₁₅BrO₉
• 分子量: 383.15
• InChiKey: IGUOKTKMTRBCHW-HHKYUTTNSA-N

物化性质

• 沸点：
  437.0±45.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  125
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 2,3,4-(tri-O-acetyl-α-D-glucopyranosyl bromide)uronate 在 吡啶 、 Candida antarctica lipase B 、 phosphate buffer 、 N,N-二异丙基乙胺 、 silver(l) oxide 作用下， 以 甲醇 、 二氯甲烷 、 异丙醇 、 甲苯 为溶剂， 反应 117.5h， 生成 (2S,3S,4S,5R,6S)-6-[(6-{[5-(benzyloxycarbonyl)-5-methylhexyl]oxy}-2,2-dimethylhexanoyl)oxy]-3,4,5-trihydroxytetrahydropyran-2-carboxylic acid
  参考文献：
  名称：

  Preparation of CI‐1027 Glucuronide: Metabolite of a Remarkable Lipid‐Modulating Agent

  摘要：

  The preparation of the 1 beta-glucuronide of the diacid, CI-1027, is described. The key synthetic steps are coupling of the mono-protected acid with bromoglucuronide, deacetylation, and enzymatic hydrolysis.

  DOI：

  10.1081/scc-200061648
• 作为产物：
  描述：

  1,2,3,4-tetra-O-acetyl-D-glucuronic acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 methyl 2,3,4-(tri-O-acetyl-α-D-glucopyranosyl bromide)uronate
  参考文献：
  名称：

  Preparation of CI‐1027 Glucuronide: Metabolite of a Remarkable Lipid‐Modulating Agent

  摘要：

  The preparation of the 1 beta-glucuronide of the diacid, CI-1027, is described. The key synthetic steps are coupling of the mono-protected acid with bromoglucuronide, deacetylation, and enzymatic hydrolysis.

  DOI：

  10.1081/scc-200061648

文献信息

• [EN] NEODEGRADER CONJUGATES<br/>[FR] CONJUGUÉS DE TYPE NEODEGRADER
  申请人：ORUM THERAPEUTICS INC

  公开号：WO2021198965A1

  公开（公告）日：2021-10-07

  The present disclosure provides neoDegraders and neoDegraders conjugated to binding moieties. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

  本公开提供了与结合基团结合的neoDegraders和neoDegraders。还提供了包含这些结合物的组合物。这些化合物和组合物对于治疗患有疾病或症状的受试者（例如癌症）是有用的。
• Synthesis of Thioesters from Carboxylic Acids via Acyloxyphosphonium Intermediates with Benzyltriethylammonium Tetrathiomolybdate as the Sulfur Transfer Reagent
  作者：Purushothaman Gopinath、Ravindran Sasitha Vidyarini、Srinivasan Chandrasekaran

  DOI：10.1021/jo9009694

  日期：2009.8.21

  An efficient protocol is reported for the synthesis of thioesters from carboxylic acids with use of acyloxy phosphonium salts as intermediates and benzyltriethylammonium tetrathiomolybdate as the sulfur transfer reagent

  据报道，使用酰氧基phospho盐作为中间体，用苄基三乙基铵四硫代钼酸铵作为硫磺转移试剂，可以有效地从羧酸合成硫酯。
• MODULATORS OF ALPHA-1 ANTITRYPSIN
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20200361939A1

  公开（公告）日：2020-11-19

  The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

  该披露提供了用于治疗α-1抗胰蛋白酶缺乏症（AATD）的化合物，其化学式为（I）：它们的互变异构体，这些化合物的药用盐，这些互变异构体的药用盐，这些化合物的氘代衍生物，这些互变异构体的氘代衍生物，以及这些盐的氘代衍生物，这些化合物的固态形式以及制备这些化合物的方法。
• METHODS FOR MAKING BIOCOMPATIBLE POLYMERIZABLE ACRYLATE PRODUCTS
  申请人：Carlson William B.

  公开号：US20150011747A1

  公开（公告）日：2015-01-08

  Sugar-acrylic monomers are synthesized to have a carbohydrate moiety linked to an acrylate group. The sugar-acrylic monomers may be polymerized to form polymers, adhesives, hydrogels, and the like. The sugar-acrylic monomers and polymers may be used in tissue engineering, adhesives and sealers, wound healing, and the like.

  糖丙烯酸单体是通过合成，将碳水化合物部分连接到丙烯酸酯基团上。糖丙烯酸单体可以聚合形成聚合物、粘合剂、水凝胶等。糖丙烯酸单体和聚合物可用于组织工程、粘合剂和密封剂、伤口愈合等。
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。